amikacin lipid nano-crystal formulation (MAT2501) / Matinas - LARVOL DELTA

Matinas BioPharma Provides Business Update and 2022 Strategic Outlook (GlobeNewswire) - "Matinas BioPharma Holdings, Inc...today is providing a business update on each of its ongoing programs and discussing its strategic outlook for 2022....A single ascending dose (SAD) study of MAT2501 in healthy volunteers is ongoing with data expected later in the second quarter of 2022. In the fourth quarter of 2021, the Cystic Fibrosis Foundation (CFF) provided an additional grant award in connection with ongoing preclinical work in support of MAT2501, bringing the total amount of CFF financial support for MAT2501 to over $4.5 million. Long-term preclinical toxicology studies planned for 2022 and protocol design for Phase 2 in consultation with the CFF are ongoing..."

Clinical protocol • Financing • New P2 trial • P1 data • Preclinical • Trial status • Cystic Fibrosis • Infectious Disease

Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights (GlobeNewswire) - "The Company expects to initiate a Phase 1 single ascending dose (SAD) pharmacokinetic study of MAT2501 in healthy volunteers in the fourth quarter of 2021. Initiation of the Phase 1 SAD study follows positive feedback received from the FDA on the Company’s ongoing preclinical toxicology and efficacy studies of MAT2501 conducted in collaboration with the Cystic Fibrosis Foundation (CFF)."

New P1 trial • Preclinical • Cystic Fibrosis

Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights (GlobeNewswire) - "The Company has advanced MAT2501 into preclinical toxicology and efficacy studies...The Company expects to initiate a Phase 2 program in cystic fibrosis patients with nontuberculous mycobacterial infections in 2022 following successful completion of the Phase 1 SAD study."

New P2 trial • Cystic Fibrosis • Nontuberculous Mycobacterial Disease

Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights (GlobeNewswire) - "MAT2501 Program Update: The Company is progressing development of MAT2501 through preclinical toxicology and efficacy studies in 2021, with the goal of completing a Phase 1 single ascending dose pharmacokinetic study in healthy volunteers by the end of 2021."

Preclinical • Trial completion date • Cystic Fibrosis

Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients (GlobeNewswire) - "Matinas BioPharma...today announced that it has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF). The award will support preclinical development of MAT2501, Matinas’ lipid nano-crystal (LNC) oral formulation of the broad-spectrum aminoglycoside amikacin, toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF)....The CFF award will allow Matinas to rapidly advance the development of MAT2501 and will support preclinical in vitro and in vivo studies."

Financing • Cystic Fibrosis • Infectious Disease

[VIRTUAL] Oral Delivery of Amikacin-Lipid NanoCrystal Formulations Safely and Effectively Treat Macrolide Resistant Mycobacteria Infections in a Mouse Model of Cystic Fibrosis (IDWeek 2020) - "ConclusionsOral administration of amikacin-LNCs safely and effectively treats macrolide resistant mycobacterial infections in a mouse model of Cystic Fibrosis."

Preclinical • Infectious Disease